(TFFP) –
-
Form 4 TFF Pharmaceuticals, For: Apr 18 Filed by: KING THOMAS BRAXTON
-
Form 4 TFF Pharmaceuticals, For: Apr 18 Filed by: Patane Michael A
-
Form 4 TFF Pharmaceuticals, For: Apr 18 Filed by: Lee Catherine Chai-zon
-
Form 4 TFF Pharmaceuticals, For: Apr 18 Filed by: MILLS ROBERT S
-
Form 4 TFF Pharmaceuticals, For: Apr 18 Filed by: Roberts Brandi
-
Form 4 TFF Pharmaceuticals, For: Apr 18 Filed by: COLEMAN KIRK ALLEN
-
Form 4 TFF Pharmaceuticals, For: Apr 18 Filed by: ROCAMBOLI STEPHEN
-
Form 4 TFF Pharmaceuticals, For: Apr 18 Filed by: Mikhak Zamaneh
-
Form 4 TFF Pharmaceuticals, For: Apr 18 Filed by: Weisman Harlan F
-
Form ARS TFF Pharmaceuticals, For: Dec 31
-
Form DEFA14A TFF Pharmaceuticals,
-
Form DEF 14A TFF Pharmaceuticals, For: Jun 04
-
Form S-1 TFF Pharmaceuticals,
-
TFF Pharmaceuticals (TFFP) Announces Additional Positive Data from the Tacrolimus Inhalation Powder Phase 2 Trial
-
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science
-
Form S-1 TFF Pharmaceuticals,
-
TFF Parmaceuticals (TFFP) PT Lowered to $13 at Jones Trading
-
Form D TFF Pharmaceuticals,
-
TFF Parmaceuticals (TFFP) PT Lowered to $36 at Roth/MKM
-
Form 8-K TFF Pharmaceuticals, For: Mar 28
-
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
-
Form 10-K TFF Pharmaceuticals, For: Dec 31
-
TFF Pharmaceuticals (TFFP) Announces Updated Data from TFF TAC and TFF VORI Clinical Programs
-
Form 8-K TFF Pharmaceuticals, For: Mar 27
-
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
-
TFF Pharmaceuticals Inc. (TFFP) Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder
-
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual Inte
-
Form 8-K TFF Pharmaceuticals, For: Mar 20
-
TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
Form 424B5 TFF Pharmaceuticals,
-
TFF Pharmaceuticals Inc. (TFFP) Prices 147.5K Share Offering at $8/sh
-
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
TFF Pharmaceuticals (TFFP) Issues Update on Clinical Programs
-
TFF Pharmaceuticals Announces Update on Clinical Programs
-
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024
-
Form SC 13G/A TFF Pharmaceuticals, Filed by: LYTTON LAURENCE W
-
TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis &am
-
TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
-
TFF Parmaceuticals (TFFP) PT Raised to $25 at Jones Trading
-
Form 8-K TFF Pharmaceuticals, For: Dec 15
-
TFF Pharmaceuticals (TFFP) Reports Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC
-
TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC
-
TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC
-
Form 4 TFF Pharmaceuticals, For: Dec 13 Filed by: KING THOMAS BRAXTON
-
Form 3 TFF Pharmaceuticals, For: Dec 11 Filed by: KING THOMAS BRAXTON
-
Form 8-K TFF Pharmaceuticals, For: Dec 11
-
TFF Pharmaceuticals (TFFP) Announces Reverse Stock Split
-
TFF Pharmaceuticals Announces Reverse Stock Split
-
TFF Pharmaceuticals (TFFP) Appoints Thomas B. King to its Board
-
TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors
Back to TFFP Stock Lookup
